Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed

Infect Immun. 2013 Jul;81(7):2584-91. doi: 10.1128/IAI.00269-13. Epub 2013 May 6.

Abstract

Interindividual variations in vaccine-induced immune responses are in part due to host genetic polymorphisms in the human leukocyte antigen (HLA) and other gene families. This study examined associations between HLA genotypes, haplotypes, and homozygosity and protective antigen (PA)-specific cellular immune responses in healthy subjects following immunization with Anthrax Vaccine Adsorbed (AVA). While limited associations were observed between individual HLA alleles or haplotypes and variable lymphocyte proliferative (LP) responses to AVA, analyses of homozygosity supported the hypothesis of a "heterozygote advantage." Individuals who were homozygous for any HLA locus demonstrated significantly lower PA-specific LP than subjects who were heterozygous at all eight loci (median stimulation indices [SI], 1.84 versus 2.95, P = 0.009). Similarly, we found that class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in LP compared with heterozygosity at those three loci. Specifically, individuals who were homozygous at these loci had significantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P = 0.005), HLA-DQA1 (median SI, 1.75 versus 2.11, P = 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P = 0.002) loci, respectively. Finally, homozygosity at an increasing number (≥ 4) of HLA loci was significantly correlated with a reduction in LP response (P < 0.001) in a dose-dependent manner. Additional studies are needed to reproduce these findings and determine whether HLA-heterozygous individuals generate stronger cellular immune response to other virulence factors (Bacillus anthracis LF and EF) than HLA-homozygous subjects.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Alleles
  • Anthrax / immunology
  • Anthrax / prevention & control
  • Anthrax Vaccines / administration & dosage
  • Anthrax Vaccines / immunology*
  • Antibody Formation
  • Bacillus anthracis / immunology*
  • Bacillus anthracis / pathogenicity
  • Cell Proliferation
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Genetic Loci
  • HLA-A Antigens / immunology
  • HLA-DQ alpha-Chains / immunology*
  • HLA-DQ beta-Chains / immunology*
  • Haplotypes
  • Heterozygote
  • Histocompatibility Testing
  • Homozygote
  • Humans
  • Immunity, Cellular*
  • Lymphocyte Activation
  • Lymphocytes / immunology
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Vaccination
  • Young Adult

Substances

  • Anthrax Vaccines
  • HLA-A Antigens
  • HLA-DQ alpha-Chains
  • HLA-DQ beta-Chains
  • HLA-DQA1 antigen
  • HLA-DQB1 antigen